{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:42:56Z","timestamp":1776861776253,"version":"3.51.2"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,10,2]],"date-time":"2002-10-02T00:00:00Z","timestamp":1033516800000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> High\u2010dose cytosine arabinoside (HDAC) is being used increasingly to treat haematological malignancies. The therapy is associated with various non\u2010haematological negative side\u2010effects, frequently involving the skin.<\/jats:p><jats:p><jats:bold>Objective<\/jats:bold> Our aim was to evaluate the actual occurrence of adverse skin reactions to HDAC over the 10\u2010year period from 1989 to 1999.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> One hundred and seventy\u2010two subjects, 118 with acute myelogenous leukaemia and 54 with acute lymphoblastic leukaemia, between 16 and 71\u00a0years of age were treated with 226 post\u2010remission consolidation regimens with HDAC (54 subjects underwent two cycles of treatment). Treatment was combined with standard doses of other cytotoxic drugs. A prospective study of the skin changes was then performed.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> The overall incidence of cutaneous reactions was almost 53%, with rashes occurring in 72.7% and 40.6% of subjects who received total doses of 30 and 24\u00a0g\/m<jats:sup>2<\/jats:sup>, respectively. In the group of subjects who received a second cycle of treatment not all of those who experienced exanthema after the first cycle (44.4%) experienced this reaction after the second cycle (only 33.3%). The most commonly observed reactions were morbilliform eruptions on the trunk and extremities and acral erythema, although severe reactions with swelling and generalized urticaria developed in some cases.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> HDAC\u2010induced cutaneous reactions in 53% of subjects. The skin changes were found to be dose related and most cleared spontaneously without requiring treatment. A clinical grading of cutaneous toxicity has been proposed to allow better comparison of cutaneous adverse effects in different reports.<\/jats:p>","DOI":"10.1046\/j.1468-3083.2002.00395.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T04:42:51Z","timestamp":1047444171000},"page":"481-485","source":"Crossref","is-referenced-by-count":42,"title":["High\u2010dose cytosine arabinoside\u2010induced cutaneous reactions"],"prefix":"10.1111","volume":"16","author":[{"given":"P","family":"Cetkovsk\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Pizinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Cetkovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,2]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"253","article-title":"High dose cytarabine: a review","volume":"2","author":"Bolwell BJ","year":"1988","journal-title":"Leukemia"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400572"},{"key":"e_1_2_5_4_2","first-page":"1191","article-title":"Cutaneous toxicity associated with high\u2010dose cytosine arabinoside","volume":"19","author":"Richards Ch","year":"1992","journal-title":"Oncol Nurs Forum"},{"key":"e_1_2_5_5_2","first-page":"129","volume-title":"Drug Eruption Reference Manual","author":"Litt J","year":"1997"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0926-9959(97)89470-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70073-B"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb02422.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70488-3"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archderm.1985.01660100020006","article-title":"Cytarabine\u2010induced palmar\u2010plantar erythema","volume":"121","author":"Walker IR","year":"1985","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1993.01680220055012","article-title":"Bullous variant of chemotherapy\u2010induced acral erythema","volume":"129","author":"Waltzer JF","year":"1993","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70342-F"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70090-G"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/archderm.1990.01670250079013","article-title":"Eccrine squamous syringometaplasia","volume":"126","author":"Hurt MA","year":"1990","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.4065\/73.3.239"},{"key":"e_1_2_5_16_2","first-page":"1800","volume-title":"Dermatology in General Medicine","author":"Yokel BK","year":"1993"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70455-X"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)80126-0"},{"key":"e_1_2_5_19_2","first-page":"501","article-title":"Dermatologic toxicity of chemotherapy","volume":"19","author":"DeSpain JD","year":"1992","journal-title":"Semin Oncol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-3083.2002.00395.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-3083.2002.00395.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:35:16Z","timestamp":1697549716000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-3083.2002.00395.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1046\/j.1468-3083.2002.00395.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-3083.2002.00395.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}